Injectable Thermoresponsive Hydrogels Modified Utilizing Novel Non‐Covalent Complexation Strategies for Sustained Release of 3DNA Nanocarriers
Journal of Biomedical Materials Research Part B: Applied Biomaterials · 2026-11 · 114 (11)
DOI: 10.1002/jbm.b.70196 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biomedical Materials Research Part B: Applied Biomaterials, online erschienen am 13.11.2026. Verfasst von Camila Vardar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biomimetic & Biohybrid Materials, Biomedical Devices, & Drug Delivery Laboratories, Department of Biomedical Engineering, Rowan University, Glassboro…. Hauptthemen laut MEDLINE: Hydrogels, DNA, Drug Carriers. Die Arbeit nennt 73 Literaturangaben. Gefördert von: Cooper Foundation, OcuMedic Inc.
Abstract (Originalsprache)
This work demonstrates, for the first time, the development of novel injectable, self‐assembling hydrogels using biomimetic complexation strategies to control and sustain the release of antibody‐targeted DNA‐based nanocarriers designed to specifically target and deplete the cells responsible for the onset of posterior capsule opacification (PCO). Naturally occurring charged homopolymers were incorporated into poly( d , l ‐lactic‐co‐glycolic acid)‐b‐poly(ethylene glycol)‐b‐poly( d , l ‐lactic‐co‐glycolic acid) (PLGA‐PEG‐PLGA) matrices to further control and extend release of 3DNA nanocarriers through electrostatic interactions. Injectable, thermosensitive gels were developed using PLGA–PEG–PLGA triblock copolymer, poly‐ l ‐lysine, and hyaluronic acid at different concentrations and molecular weights for the sustained release of targeted nucleic acid nanocarriers loaded with cytotoxic doxorubicin (G8:3DNA:Dox). Characterization studies included optical clarity, critical gelation temperature (GT), and sustained drug release kinetics. The formulations showed great specificity for myofibroblast precursors with minimal off‐target effects. Hydrogels are in situ forming, nontoxic, and optically clear at 37°C, and therefore can be irrigated over the lens capsule at the time of surgery. Modification with charged homopolymers extended release from 1 up to 5 months. Our findings from ex vivo studies show that extending delivery of a low dose of DNA‐based nanocarriers by exploiting long‐chain non‐covalent interactions led to targeted depletion of myofibroblasts and progenitor cells below levels that do not cause wrinkling or visual abnormalities. This system has the potential to be used with every cataract surgery patient and decrease the incidence of PCO and associated complications. Moreover, this gel can be adapted to deliver various other types of therapeutics into the eye.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomimetic & Biohybrid Materials, Biomedical Devices, & Drug Delivery Laboratories, Department of Biomedical Engineering, Rowan University, Glassboro, New Jersey, USA.
- OcuMedic Inc., Mullica Hill, New Jersey, USA.
- Department of Chemical Engineering, Rowan University, Glassboro, New Jersey, USA.
ORCID-Profile: Camila Vardar, Mark E Byrne
Förderung
- Cooper Foundation
- OcuMedic Inc
Zitieren
APA
Vardar, C., Trojan, G., & Byrne, M. E. (2026). Injectable Thermoresponsive Hydrogels Modified Utilizing Novel Non‐Covalent Complexation Strategies for Sustained Release of 3DNA Nanocarriers. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 114(11). https://doi.org/10.1002/jbm.b.70196
Vancouver
Vardar C, Trojan G, Byrne ME. Injectable Thermoresponsive Hydrogels Modified Utilizing Novel Non‐Covalent Complexation Strategies for Sustained Release of 3DNA Nanocarriers. Journal of Biomedical Materials Research Part B: Applied Biomaterials. 2026;114(11). doi:10.1002/jbm.b.70196
BibTeX
@article{Vardar2026,
author = {Vardar, Camila and Trojan, Giavanna and Byrne, Mark E},
title = {Injectable Thermoresponsive Hydrogels Modified Utilizing Novel Non‐Covalent Complexation Strategies for Sustained Release of 3DNA Nanocarriers},
journal = {Journal of Biomedical Materials Research Part B: Applied Biomaterials},
year = {2026},
volume = {114},
number = {11},
doi = {10.1002/jbm.b.70196}
}
EUVIMED